Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Executive Summary
Bristol-Myers Squibb will undertake a cost-cutting program to offset the impact of the development delay of the investigational type 2 diabetes drug Pargluva.